ERBB2 and breast carcinoma: In in silico analysis, we investigated the expression of 20 keratins in 54 breast cancer cell lines (GSE69017, Figure S1) and could show that KRT16 was upregulated in 24% (13/54) of breast cancer cell lines of predominantly the basal-like (53.8%), ERBB2 enriched (23%), claudin-low (15%), and normal-like (7.7%) subtypes that mainly overexpress CDH1 and VIM, whereas KRT16 was downregulated in cell-lines of the luminal A and luminal B molecular subtypes.